Angiogenesis Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1118, 1081 HV, Amsterdam, The Netherlands.
Angiogenesis Laboratory, Department of Radiation Oncology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1118, 1081 HV, Amsterdam, The Netherlands.
Angiogenesis. 2018 Aug;21(3):545-555. doi: 10.1007/s10456-018-9607-8. Epub 2018 Mar 2.
Galectin-9 consists of two peptide-linked carbohydrate recognition domains (CRDs), but alternative splicing and proteolytic processing can give rise to multiple galectin-9 isoforms. Some of these consist of a single CRD and can exert different functions in cell biology. Here, we explored the role of these galectin-9 isoforms in endothelial cell function and angiogenesis. For this, we compared the effects of the two separate CRDs (Gal-9N and Gal-9C) with the tandem repeat galectin-9M on endothelial cell proliferation, migration, sprouting and tube formation in vitro as well as on angiogenesis in vivo using the chicken chorioallantoic membrane (CAM) assay. Galectin-9 isoforms significantly affected proliferation in quiescent endothelial cells and migration in activated endothelial cells. Interestingly, both monovalent gal-9 CRDs displayed opposite effects compared to gal-9M on proliferation and migration. Sprouting was significantly inhibited by gal-9C, while all isoforms appeared to stimulate tube formation. Angiogenesis in vivo was hampered by all three isoforms with predominant effects on vessel length. In general, the isoforms induced only subtle concentration-dependent effects in vitro as well as in vivo. Collectively, the effects of different galectin-9 isoforms in endothelial cell biology depend on the cellular activation status. While opposing effects can be observed on a cellular level in vitro, all galectin-9 isoforms hamper angiogenesis in vivo. This warrants further investigation of the regulatory mechanisms that underlie the diverging roles of galectin-9 isoforms in endothelial cell biology since this could provide therapeutic opportunities.
半乳糖凝集素-9 由两个肽连接的碳水化合物识别结构域(CRD)组成,但选择性剪接和蛋白水解处理可以产生多种半乳糖凝集素-9 同工型。其中一些由单个 CRD 组成,在细胞生物学中可以发挥不同的功能。在这里,我们研究了这些半乳糖凝集素-9 同工型在血管内皮细胞功能和血管生成中的作用。为此,我们比较了两个单独的 CRD(Gal-9N 和 Gal-9C)以及串联重复 Gal-9M 对内皮细胞增殖、迁移、发芽和体外管状形成以及鸡胚尿囊膜(CAM)试验体内血管生成的影响。半乳糖凝集素-9 同工型显著影响静止内皮细胞的增殖和激活内皮细胞的迁移。有趣的是,与 Gal-9M 相比,单价 gal-9 CRD 对增殖和迁移均表现出相反的作用。Gal-9C 显著抑制发芽,而所有同工型似乎都刺激管状形成。三种同工型都抑制体内血管生成,主要影响血管长度。一般来说,同工型在体外和体内仅引起轻微的浓度依赖性效应。总的来说,不同半乳糖凝集素-9 同工型在血管内皮细胞生物学中的作用取决于细胞的激活状态。虽然在体外细胞水平上可以观察到相反的作用,但所有半乳糖凝集素-9 同工型都抑制体内血管生成。这需要进一步研究半乳糖凝集素-9 同工型在血管内皮细胞生物学中作用差异的调节机制,因为这可能为治疗提供机会。